Emily has 20 years’ experience in cell and molecular biology applied to drug discovery.
Emily’s academic research involved the development and validation of stem cell derived models of disease and has subsequently led teams in large global pharma and biotech companies, developing cellular assays for both screening and phenotypic analysis of large and small molecule drugs, from target identification and validation through to candidate drug selection.
Emily is currently working at Medicines Discovery Catapult as Head of Cellular Sciences, supporting SMEs, academics and drug discovery researchers to evaluate their drug or technology. Her team applies cell and molecular biology expertise in vitro using cellular models coupled with advanced technologies to evaluate cellular response. From target engagement to phenotypic response, the team aims to build translational evidence for a partners asset aligned to their key goals.